Rosuvastatin
Product Images NDC 17856-0183

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rosuvastatin (NDC 17856-0183). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (17856 0183 01 Case Label)

This text is a label for Rosuvastatin tablets, USP, containing 5mg per tablet. It provides instructions to protect from moisture, store between 20-25°C, with excursions permitted between 15-30°C. It also reminds to keep the medication out of the reach of children. The package contains 100 tablets and includes details like GTIN, K SIN, lot number, and information about the manufacturer and distributor. It suggests contacting for reordering.*

FDA Label Image

Image Description (17856 0186 01 Case Label)

This text is a description of Rosuvastatin tablets with a dosage of 10mg per tablet. The tablets are to be stored between 20°C-25°C (68°F-77°F) with permissible excursions between 15°C-30°C (59°F-86°F). It also includes information on protecting the tablets from moisture, keeping them in a child-resistant container, and keeping medications out of reach of children. The text also mentions the dosage, packaging details, expiration date, and manufacturer information.*

FDA Label Image

Figure-01 (Figure 1)

This text appears to be presenting statistical data related to a study or trial involving RSV (Respiratory Syncytial Virus) and a placebo group. The text includes information on the number at risk and the duration in years of the study for both groups. Additionally, it provides values such as hazard ratios with confidence intervals and p-values. This data may be useful for analyzing and comparing the effectiveness of the treatment against the placebo in the context of RSV.*

FDA Label Image

Figure-02 (Figure 2)

This text provides information from a study comparing the effects of Rosuvastatin 20 mg versus a placebo of 20 mg on various cardiovascular events in a group of 8901 participants. The results show significant differences in the occurrence of primary endpoints, cardiovascular death, nonfatal stroke, nonfatal MI, hospitalized unstable angina, and arterial revascularization between the two groups. The Hazard Ratios and confidence intervals are also provided for each event, along with p-values to indicate statistical significance. Overall, the text presents valuable data on the impact of Rosuvastatin on cardiovascular outcomes.*

FDA Label Image

Figure-02 (Figure 3)

FDA Label Image

Structural Formula (Rosuvastatin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.